The Pulmonary Fibrosis Foundation (PFF) recently announced that registration for PFF Summit 2015: From Bench to Bedside is now open. This is an international conference focused on pulmonary fibrosis (PF), a deadly disease that results from lung scarring. The Summit will address medical education for healthcare professionals, conduct sessions dedicated to those that live with…
News
A team led by researchers at School of Pharmacy, Hampton University in Virginia recently discovered new key players in pulmonary fibrosis development and related angiogenesis. The study was published in the Journal of Cellular Biochemistry and is entitled “Nitric Oxide Mediates Bleomycin-Induced Angiogenesis and…
iBio, Inc, a leading pharmaceutical company using plant-based technology for developing and manufacturing biological products, has announced that it is now collaborating with Caliber Biotherapeutics LLC, which will be responsible for scaling-up and producing the necessary equipment for clinical development of iBio, Inc.’s lead anti-fibrosis product, IBIO-CFB03.
Molecular diagnostics company Veracyte, Inc., which is developing a genomic test to help improve diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has announced the establishment of a definitive agreement for the trade of common stocks, worth $40 million, in a private placement. Investors acquired 4,907,975 shares of common stock at a purchase price of…
Researchers at Stanford University School of Medicine have come up with what appears to be one of the major keys in deciphering the mysteries of scarring. Their findings also included a molecule that could possibly reduce scarring and induce wound healing at the same time. Possibilities of this molecule being effective in…
The molecular diagnostic company Veracyte, Inc. and the multinational conglomerate corporation GE have established a research partnership focused on developing novel solutions able to improve the diagnosis of diseases such as Idiopathic pulmonary fibrosis (IPF). The companies did not disclose the financial terms of the collaboration. Veracyte will work…
In a new study entitled “Plasticity of Hopx+ type I alveolar cells to regenerate type II cells in the lung,” researchers report a new unrecognized capacity of adult lung cells, type I cells, to revert into another cell type (type II cells), spurring on lung regeneration…
Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that leads programs focused on erectile dysfunction and diseases of excessive scarring (fibrosis), announced that the US Patent Office (PO) has released a Notice Of Allowability for the Company’s patent application, Compositions and Methods for the treatment of fibroproliferative conditions. Doug Unwin,…
A study recently published in the journal Lancet Respiratory Medicine revealed a novel set of potential biomarkers that can be used as predictors of idiopathic pulmonary fibrosis (IPF) disease progression. The study is entitled “Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary…
In a new study entitled “Tryptase is involved in the development of early ventilator-induced pulmonary fibrosis in sepsis-induced lung injury,” researchers identified mechanical ventilation as an inducer of pulmonary fibrosis by modulating secretion of pro-fibrotic factors. The study was published in the journal Critical…
